Skip to content
Artwork for Cell & Gene: The Podcast
Cell & Gene: The Podcast · July 2 · 22 min

Exploring Dendritic Cell Therapy for Solid Tumors with Diakonos Oncology's Jay Hartenbach

We love to hear from our listeners. Send us a message. Episode 132 of Cell & Gene: The Podcast features Host, Erin Harris' conversation with Diakonos Oncology's President and COO, Jay Hartenbach. Together, they explore how the company is advancing a patient-derived dendritic cell therapy designed to generate a stronger immune response against difficult-to-treat solid tumors, including glioblastoma, pancreatic cancer, and refractory melanoma. Their discussion also covers early clinical signals, outpatient administration, and the manufacturing and automation steps needed to make personalized cell therapies more scalable for broader CGT audiences. Subscribe to the podcast! Apple | Spotify | YouTube Visit my website: Cell & Gene Connect with me on LinkedIn

0:00-22:57

transcript

No transcript — this publisher did not publish one.

show notes

We love to hear from our listeners. Send us a message.

Episode 132 of Cell & Gene: The Podcast features Host, Erin Harris' conversation with Diakonos Oncology's President and COO, Jay Hartenbach. Together, they explore how the company is advancing a patient-derived dendritic cell therapy designed to generate a stronger immune response against difficult-to-treat solid tumors, including glioblastoma, pancreatic cancer, and refractory melanoma. Their discussion also covers early clinical signals, outpatient administration, and the manufacturing and automation steps needed to make personalized cell therapies more scalable for broader CGT audiences.

Subscribe to the podcast!
Apple  |  SpotifyYouTube

Visit my website: Cell & Gene

Connect with me on LinkedIn

links6